Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 323-327

  Phillips, Beth Bryles ^a,b   Digmann, Rachel R ^a,c   Beck, M Gwen ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Hepatic transaminases; Hepatotoxicity; Venlafaxine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; FEMALE; HEPATITIS; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MENOPAUSAL SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; RARE DISEASE; VASOMOTOR DISORDER;

CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS, TOXIC; HOT FLASHES; HUMANS; LIVER FUNCTION TESTS; MIDDLE AGED; POSTMENOPAUSE;

EID: 33144485234     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G339     Document Type: Article

References (19)

1. Miller RG. Menopause and beyond. In: Barker LR, Burton JR, Zieve PD, eds. Principles of ambulatory medicine. 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2003.
2. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med 1974;28:108-15.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
5. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:237-81.
6. Barton D, LaVasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002;29:33-40.
7. Trivestin ingredients, www.4jointhealth.com/trivestin.html (accessed 2006 Jan 11).
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. Package insert. Effexor XR (venlafaxine). Philadelphia: Wyeth Pharmaceuticals, November 2003.
10. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
11. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16(suppl):54S-61S.
12. Spigset O, Hagg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003;18:157-61.
13. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999;9:435-43.
14. Kohnke MD, Griese EU, Stosser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002;35:116-8.
15. Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis (letter). Ann Pharmacother 2004;38:352-3. Epub 23 Dec 2003. DOI 10.1345/aph.1D205
16. Kim KY, Hwang W, Narendran R. Acute liver damage possibly related to sertraline and venlafaxine ingestion (letter). Ann Pharmacother 1999;33:381-2. DOI 10.1345/aph.18155
17. Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis (letter). Ann Intern Med 1999;130:944.
18. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis (letter). Ann Intern Med 2000;132:417.
19. Pradeep RJ, Victor G, Iby N, Kurpad SS, Galgali RB, Srinivasan K. Venlafaxine induced hepatitis (letter). J Assoc Physicians India 2004;52:340.